These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 28094136)

  • 1. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study.
    Bally L; Thabit H; Kojzar H; Mader JK; Qerimi-Hyseni J; Hartnell S; Tauschmann M; Allen JM; Wilinska ME; Pieber TR; Evans ML; Hovorka R
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):261-270. PubMed ID: 28094136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
    Tauschmann M; Thabit H; Bally L; Allen JM; Hartnell S; Wilinska ME; Ruan Y; Sibayan J; Kollman C; Cheng P; Beck RW; Acerini CL; Evans ML; Dunger DB; Elleri D; Campbell F; Bergenstal RM; Criego A; Shah VN; Leelarathna L; Hovorka R;
    Lancet; 2018 Oct; 392(10155):1321-1329. PubMed ID: 30292578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial.
    Benhamou PY; Franc S; Reznik Y; Thivolet C; Schaepelynck P; Renard E; Guerci B; Chaillous L; Lukas-Croisier C; Jeandidier N; Hanaire H; Borot S; Doron M; Jallon P; Xhaard I; Melki V; Meyer L; Delemer B; Guillouche M; Schoumacker-Ley L; Farret A; Raccah D; Lablanche S; Joubert M; Penfornis A; Charpentier G;
    Lancet Digit Health; 2019 May; 1(1):e17-e25. PubMed ID: 33323237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study.
    Boughton CK; Hartnell S; Thabit H; Mubita WM; Draxlbauer K; Poettler T; Wilinska ME; Hood KK; Mader JK; Narendran P; Leelarathna L; Evans ML; Hovorka R
    Lancet Healthy Longev; 2022 Mar; 3(3):e135-e142. PubMed ID: 35359882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study.
    Thabit H; Lubina-Solomon A; Stadler M; Leelarathna L; Walkinshaw E; Pernet A; Allen JM; Iqbal A; Choudhary P; Kumareswaran K; Nodale M; Nisbet C; Wilinska ME; Barnard KD; Dunger DB; Heller SR; Amiel SA; Evans ML; Hovorka R
    Lancet Diabetes Endocrinol; 2014 Sep; 2(9):701-9. PubMed ID: 24943065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.
    Bally L; Thabit H; Tauschmann M; Allen JM; Hartnell S; Wilinska ME; Exall J; Huegel V; Sibayan J; Borgman S; Cheng P; Blackburn M; Lawton J; Elleri D; Leelarathna L; Acerini CL; Campbell F; Shah VN; Criego A; Evans ML; Dunger DB; Kollman C; Bergenstal RM; Hovorka R
    BMJ Open; 2017 Jul; 7(7):e016738. PubMed ID: 28710224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial.
    Kariyawasam D; Morin C; Casteels K; Le Tallec C; Sfez A; Godot C; Huneker E; Garrec N; Benhamou PY; Polak M; Charpentier G; Franc S; Beltrand J
    Lancet Digit Health; 2022 Mar; 4(3):e158-e168. PubMed ID: 35216750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the efficacy, safety and utility of 6-month day-and-night automated closed-loop insulin delivery under free-living conditions compared with insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, multicentre, multinational, single-period, randomised, parallel group study protocol.
    Musolino G; Allen JM; Hartnell S; Wilinska ME; Tauschmann M; Boughton C; Campbell F; Denvir L; Trevelyan N; Wadwa P; DiMeglio L; Buckingham BA; Weinzimer S; Acerini CL; Hood K; Fox S; Kollman C; Sibayan J; Borgman S; Cheng P; Hovorka R
    BMJ Open; 2019 Jun; 9(6):e027856. PubMed ID: 31164368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flexible insulin therapy with a hybrid regimen of insulin degludec and continuous subcutaneous insulin infusion with pump suspension before exercise in physically active adults with type 1 diabetes (FIT Untethered): a single-centre, open-label, proof-of-concept, randomised crossover trial.
    Aronson R; Li A; Brown RE; McGaugh S; Riddell MC
    Lancet Diabetes Endocrinol; 2020 Jun; 8(6):511-523. PubMed ID: 32445738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.
    Russell SJ; Hillard MA; Balliro C; Magyar KL; Selagamsetty R; Sinha M; Grennan K; Mondesir D; Ekhlaspour L; Zheng H; Damiano ER; El-Khatib FH
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):233-243. PubMed ID: 26850709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
    Kropff J; Del Favero S; Place J; Toffanin C; Visentin R; Monaro M; Messori M; Di Palma F; Lanzola G; Farret A; Boscari F; Galasso S; Magni P; Avogaro A; Keith-Hynes P; Kovatchev BP; Bruttomesso D; Cobelli C; DeVries JH; Renard E; Magni L;
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):939-47. PubMed ID: 26432775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Day-and-Night Hybrid Closed-Loop Insulin Delivery in Adolescents With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial.
    Tauschmann M; Allen JM; Wilinska ME; Thabit H; Stewart Z; Cheng P; Kollman C; Acerini CL; Dunger DB; Hovorka R
    Diabetes Care; 2016 Jul; 39(7):1168-74. PubMed ID: 26740634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Suboptimally Controlled Adolescents With Type 1 Diabetes: A 3-Week, Free-Living, Randomized Crossover Trial.
    Tauschmann M; Allen JM; Wilinska ME; Thabit H; Acerini CL; Dunger DB; Hovorka R
    Diabetes Care; 2016 Nov; 39(11):2019-2025. PubMed ID: 27612500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
    Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
    Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial.
    Daly AB; Boughton CK; Nwokolo M; Hartnell S; Wilinska ME; Cezar A; Evans ML; Hovorka R
    Nat Med; 2023 Jan; 29(1):203-208. PubMed ID: 36631592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial.
    Boughton CK; Bally L; Martignoni F; Hartnell S; Herzig D; Vogt A; Wertli MM; Wilinska ME; Evans ML; Coll AP; Stettler C; Hovorka R
    Lancet Diabetes Endocrinol; 2019 May; 7(5):368-377. PubMed ID: 30935872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial.
    Ware J; Boughton CK; Allen JM; Wilinska ME; Tauschmann M; Denvir L; Thankamony A; Campbell FM; Wadwa RP; Buckingham BA; Davis N; DiMeglio LA; Mauras N; Besser REJ; Ghatak A; Weinzimer SA; Hood KK; Fox DS; Kanapka L; Kollman C; Sibayan J; Beck RW; Hovorka R;
    Lancet Digit Health; 2022 Apr; 4(4):e245-e255. PubMed ID: 35272971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unsupervised home use of an overnight closed-loop system over 3-4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes.
    Thabit H; Elleri D; Leelarathna L; Allen JM; Lubina-Solomon A; Stadler M; Walkinshaw E; Iqbal A; Choudhary P; Wilinska ME; Barnard KD; Heller SR; Amiel SA; Evans ML; Dunger DB; Hovorka R
    Diabetes Obes Metab; 2015 May; 17(5):452-8. PubMed ID: 25492378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-blind, randomised, crossover study to reduce hypoglycaemia risk during postprandial exercise with closed-loop insulin delivery in adults with type 1 diabetes: announced (with or without bolus reduction) vs unannounced exercise strategies.
    Tagougui S; Taleb N; Legault L; Suppère C; Messier V; Boukabous I; Shohoudi A; Ladouceur M; Rabasa-Lhoret R
    Diabetologia; 2020 Nov; 63(11):2282-2291. PubMed ID: 32740723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.